Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).

This is because the technology is an option alongside current standard treatment options and we do not think practice will change substantially as a result of this guidance.

The list price of brodalumab has a discount that is commercial in confidence. For enquiries about the patient access scheme contact ukmarketaccess@leo-pharma.com.

A resource impact template is available alongside this statement to enable users to calculate the resource impact of the guidance.

This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.


This page was last updated: